Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : U.S. FDA approves AstraZeneca diabetes drug for treating heart failure risk

share with twitter share with LinkedIn share with facebook
share via e-mail
10/21/2019 | 03:06am EST
FILE PHOTO: A man walks past a sign at an AstraZeneca site in Macclesfield

(Reuters) - AstraZeneca diabetes drug Farxiga has been approved for use in the United States as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks, the British drugmaker said on Monday.

The approval by the U.S. Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial, the London-listed company said, and follows a similar approval https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-label-updated-in-the-eu-in-type-2-diabetes.html by the European authorities in August.

Farxiga is the first of its class to be approved in the United States for this indication, Ruud Dobber, executive vice president of BioPharmaceuticals at AstraZeneca said.

"This is promising news for the 30 million people living with type-2 diabetes in the United States, as heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke," Dobber said.

Farxiga, already approved as a treatment for type-2 diabetes, is part of the SGLT2-inhibitor class of antidiabetics that cause the kidneys to expel blood sugar from the body through urine.

Diabetes is often associated with a high risk of heart failure, a condition in which the blood-pumping organ does not circulate blood as well as it should.

The treatment, one of AstraZeneca's top 10 drugs by sales, had shown promise in reducing the risk of heart attacks or disease progression in patients with the HFrEF subtype of heart failure, accounting for about half of heart failure cases.

The FDA has already placed Farxiga under speedy reviews to treat some kinds of heart failure and kidney failure.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
11:48aASTRAZENECA :  Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevatio..
10:46aASTRAZENECA : Consistent Effects of FARXIGA in Heart Failure Patients With Reduc..
11/15ASTRAZENECA : Type-2 Diabetes Drug Qtrilmet Approved in the EU
11/15ASTRAZENECA : Qtrilmet approved in the EU for treatment of T2D
11/14ASTRAZENECA : Launches Diabetes Can Break Your Heart
11/14Merck, AstraZeneca Get FDA Priority Review for Selumetinib in NF1
11/14MERCK AND : US FDA accepts regulatory submission for selumetinib in neurofibroma..
11/13LONDON STOCK EXCHANGE : FTSE dips on murky trade view; Tullow tanks on mid-caps
11/11ROXADUSTAT POOLED ANALYSES : no increased CV risk
11/08FibroGen, AstraZeneca Up After Roxadustat Data
More news
Financials (USD)
Sales 2019 24 471 M
EBIT 2019 6 592 M
Net income 2019 2 125 M
Debt 2019 11 723 M
Yield 2019 3,00%
P/E ratio 2019 55,8x
P/E ratio 2020 37,4x
EV / Sales2019 5,49x
EV / Sales2020 4,99x
Capitalization 123 B
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 99,59  $
Last Close Price 93,51  $
Spread / Highest target 44,4%
Spread / Average Target 6,50%
Spread / Lowest Target -24,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA23.41%122 645
JOHNSON & JOHNSON1.48%355 145
ROCHE HOLDING AG20.79%255 382
MERCK AND COMPANY11.11%216 154
PFIZER-14.59%206 312
NOVARTIS18.75%202 726